secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001798749-23-000062
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate completes Phase 2b enrollment (202 patients) and enrolls first Phase 3 patient in AV-101 PAH trial
--------------------------------------------------------------------------------

- Phase 2b portion of IMPAHCT trial enrolled 202 adult patients with PAH.
- First patient enrolled in Phase 3 portion under adaptive trial design.
- Topline Phase 2b data expected in June 2024.
- Over 120 sites actively recruiting for Phase 3 globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/0001798749-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/tmb-20231120x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer